Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib

Abstract

New‐generation tyrosine kinase inhibitors ( TKI ) are promising agents for the treatment of chronic myeloid leukemia ( CML ), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.